Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 2
2004 4
2005 2
2006 2
2007 4
2008 2
2009 4
2010 7
2011 8
2012 12
2013 13
2014 17
2015 12
2016 7
2017 13
2018 5
2019 6
2020 17
2021 19
2022 7
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

149 results
Results by year
Filters applied: . Clear all
Page 1
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T. Coles AJ, et al. Among authors: fernandez o. Mult Scler. 2022 Apr;28(5):842-846. doi: 10.1177/13524585211061335. Epub 2021 Dec 9. Mult Scler. 2022. PMID: 34882037 Free PMC article. Review.
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Ramo Tello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS; MESEMS investigators. Uccelli A, et al. Among authors: fernandez o. Lancet Neurol. 2021 Nov;20(11):917-929. doi: 10.1016/S1474-4422(21)00301-X. Lancet Neurol. 2021. PMID: 34687636
[Biomarkers in multiple sclerosis].
Fernández Ó, Arroyo-González R, Rodríguez-Antigüedad A, García-Merino JA, Comabella M, Villar LM, Izquierdo G, Tintoré M, Oreja-Guevara C, Álvarez-Cermeño JC, Meca-Lallana JE, Prieto JM, Ramió-Torrentà L, Martínez-Yélamos S, Montalban X. Fernández Ó, et al. Rev Neurol. 2013 Apr 1;56(7):375-90. Rev Neurol. 2013. PMID: 23520007 Free article. Review. Spanish.
[Future challenges in multiple sclerosis].
Fernández Ó. Fernández Ó. Med Clin (Barc). 2014 Dec;143 Suppl 3:44-7. doi: 10.1016/S0025-7753(15)30010-5. Med Clin (Barc). 2014. PMID: 25732950 Review. Spanish.
Combination therapy in multiple sclerosis.
Fernández O. Fernández O. J Neurol Sci. 2007 Aug 15;259(1-2):95-103. doi: 10.1016/j.jns.2006.08.019. Epub 2007 May 15. J Neurol Sci. 2007. PMID: 17507031 Review.
Biomarkers in multiple sclerosis: an update for 2014.
Fernandez O, Martin R, Rovira A, Llufriu S, Vidal-Jordana A, Fernandez-Sanchez VE, Alvarez-Cermeno JC, Izquierdo G, Arroyo-Gonzalez R, Rodriguez-Antiguedad A, Casanova-Estruch B, Montalban X. Fernandez O, et al. Rev Neurol. 2014 Jun 16;58(12):553-70. Rev Neurol. 2014. PMID: 24915032 Free article. Review. English, Spanish.
Estimate of the cost of multiple sclerosis in Spain by literature review.
Fernández O, Calleja-Hernández MA, Meca-Lallana J, Oreja-Guevara C, Polanco A, Pérez-Alcántara F. Fernández O, et al. Expert Rev Pharmacoecon Outcomes Res. 2017 Aug;17(4):321-333. doi: 10.1080/14737167.2017.1358617. Epub 2017 Jul 28. Expert Rev Pharmacoecon Outcomes Res. 2017. PMID: 28726515 Review.
149 results